Purpose: Haploinsufficiency of DYRK1A causes a recognizable clinical syndrome. The goal of this paper is to investigate congenital anomalies of the kidney and urinary tract (CAKUT) and genital defects (GD) in patients with DYRK1A mutations.
INTRODUCTION
The dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK) family of protein kinases are conserved across species from lower eukaryotes to mammals. 1 DYRK family members are activated by autophosphorylating a tyrosine residue in their activation loop. 2 DYRK1A is the most extensively characterized member of the DYRK family, which in humans, is encoded by the DYRK1A gene located in the Down syndrome critical region of chromosome 21. 3 A growing body of literature implicates a strong causal relationship between DYRK1A haploinsufficiency and a recognizable syndrome known as DYRK1A-related intellectual disability syndrome. [3] [4] [5] In addition to intellectual disability (ID), other frequently occurring features include; intrauterine growth retardation (IUGR), difficulty feeding (DF) with failure to thrive (FTT), microcephaly, seizures, dysmorphic facial features, and developmental delays (DD), 5 while additional phenotypic features are observed less commonly. 5, 6 While many features of this syndrome are well-characterized; the full phenotypic spectrum has yet to be defined. This manuscript presents a cohort of individuals with de novo (when both parental samples available) DYRK1A single nucleotide variants (SNVs) or small deletions ≤10 base pairs and defines CAKUT/GD that have not been previously described in patients with DYRK1A syndrome. We also provide supporting evidence, using Xenopus laevis embryos as a model, that DYRK1A is required for GU development and that a pathogenic variant of human DYRK1A is directly responsible for the CAKUT/GD phenotype. Together, these findings support the investigation of potential CAKUT/GD in the clinical workup of patients with DYRK1A-related ID syndrome.
MATERIALS AND METHODS

Study participants
The index patient was seen in the Renal Genetics Clinic (RGC) at Texas Children's Hospital (TCH). Subsequently, patients who had ES in a clinical diagnostic laboratory [Baylor Genetics (BG)] were queried for de novo (except P1, P12 and P15) pathogenic [except P10 (likely pathogenic), P5, P7, and P17 called as VUS in the initial report] variants in DYRK1A. Inclusion criteria also included: 1) variant confirmation using Sanger sequencing, and 2) lack of other mutations that could explain the phenotype observed. Exclusion criteria included multiple additional candidate genes that may be related to the phenotype. The final size of our cohort after applying those filters is 19 patients. Clinical phenotype information was collected from initial ES requisition form or contacting referring physicians. The Institutional Review Board approved the study protocol for the Protection of Human Subjects at Baylor College of Medicine.
ES and data analysis
ES was performed by previously published methods at BG. 7, 8, 9 In brief, an Illumina paired-end pre-capture library was constructed with 1ug of DNA, according to the manufacturer's protocol (Illumina Multiplexing_SamplePrep_Guide_-1005361_D), with modifications as described in the BCM-HGSC Illumina Barcoded Paired-End Capture Library Preparation protocol. 7 Four pre-captured libraries were pooled and then hybridized in solution to the HGSC CORE design (52Mb, NimbleGen) according to the manufacturer's protocol NimbleGen SeqCap EZ Exome Library SR User's Guide (Version 2.2), with minor revisions. Sequencing was performed in paired-end mode with the Illumina HiSeq 2000 platform, with sequencing-by-synthesis reactions extended for 101 cycles from each end with an additional cycle for the index read.
With a sequencing yield of 12 Gb, 92% of the targeted exome bases were covered to a depth of 20X or greater. Illumina sequence analysis was performed with the HGSC Mercury analysis pipeline (https://www.hgsc.bcm.edu-/software/mercury), which moves data through various analysis tools from the initial sequence generation on the instrument to annotated variant calls (SNVs and intra-read indels). Variant interpretation was performed according to the most recent guidelines published by the American College of Medical Genetics and Genomics (ACMG). 10 Accordingly, only variants that met strict criteria were called pathogenic. Sanger sequencing confirmed all variants reported in this paper.
Xenopus laevis embryos and microinjections
Xenopus females were induced to produce eggs by injection of human chorionic gonadotropin.
Eggs were obtained by standard means, placed in 0.3x MMR (Marc's modified Ringers solution, 33 mM NaCl, 0.66 mM KCl, 0.33 mM MgSO4, 0.66 mM CaCl2, 1.66 mM HEPES pH 7.4) and fertilized in vitro. Blastula cleavage stages and dorsal versus ventral polarity were determined by established methods. 11 Microinjections were targeted to the V2 blastomere at the eight-cell stage, which provides major contributions to the development of the pronephros. [12] [13] [14] Ten nL of injection mix (described below) was injected into embryos. Ten ng of Dyrk1a morpholino 5'-TGCATCGTCC-TCTTTCAAGTCTCAT-3′ 15 or Standard morpholino 5′-CCTCTTACCTCAGTTACAATTTATA-3′ was co-injected with 50 pg RNA (either control βgalactosidase, human DYRK1A, or patient mutant DYRK1A R205* ) along with 1 ng membrane-RFP RNA 16 as a lineage tracer to verify that the correct blastomere was injected.
Immunostaining
Embryos were staged, 11 
Construct design and in vitro transcription
Cloning for Western blot analysis was executed by generating PCR cDNA from a pCS2-Xenopus-Dyrk1a-HA construct 15 using a Bio-Rad C1000 Touch™ Thermal Cycler (Bio-Rad, Hercules, CA, USA), following Addgene's protocol for PCR cloning. PCR with OneTaq (NEB, Ipswich, MA, USA) was used to amplify wildtype Xenopus dyrk1a excluding the nucleotides coding for the stop codon. Forward primer 5'-TTTGGATCCATGCATACAGGAGGAGAGAC-3' was used to create the control dyrk1a construct while forward primer 5'-TTTGGATCCATGA-GACTTGAAAGAGGACGATGCATACAGGAGGAGAGAC-3' was used to create the dyrk1a + 5' UTR construct, which added part of Dyrk1a's endogenous 5' UTR that is recognized by the Dyrk1a MO. The same reverse primer 5'-TTTTTTCTAGACGAGCTTGCCACAGGACTCTG-3' was used to generate both cDNA fragments. BamHI and XbaI were used to insert cDNA fragments into a pCS2-GFP vector, placing the construct immediately upstream and in-frame with a GFP tag. Cloning for the rescue experiment was executed by traditional cloning methods and PCR cloning. The wildtype human DYRK1A cDNA was cut from the pMH-SFB-DYRK1A construct (Addgene, Cambridge, MA, USA) and inserted into pCS2-HA vector using XhoI and contains a gateway vector site 5' to the cDNA. PCR cloning was used to generate the DYRK1A R205* truncated mutation. Forward primer 5'-AATGCGGAATTCAGACAAG-TTTGTACAAAAAAGCAGGC-3' and reverse primer 5'-TAGAGGCTCGAGTCACACTTCTATC-TGTGCTTGATTCAG-3' were used to amplify the truncated cDNA plus the gateway vector site 5' to the cDNA from the wildtype human pCS2-HA-DYRK1A vector. The truncated cDNA was then inserted into a pCS2-HA vector using EcoRI and XhoI sites. Prior to in vitro transcription, the reading frame of each construct was confirmed by Sanger sequencing (Eurofins, Luxembourg). The cDNA templates were linearized for transcription using NotI. Capped RNAs encoding the constructs were generated using the SP6 mMessage mMachine Kit (Thermo Fisher Scientific, Waltham, MA, USA). The transcribed RNA products were evaluated by a 1% agarose gel using RNA gel loading dye and by optical density (OD 280/260) obtained from a NanoDrop® ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
Western blots
To validate knockdown of protein expression by Dyrk1a MO, Western blot analysis was carried out on lysates derived from embryos injected at the single cell stage. Forty ng of either Dyrk1a morpholino 5-TGCATCGTCCTCTTTCAAGTCTCAT-3′ 15 or standard morpholino 5′-CCTCTTACCTCAGTTACAATTTATA-3′ (Gene Tools LLC, Philomath, OR, USA) was coinjected with 1 ng RNA (either Xenopus dyrk1a control, or Xenopus dyrk1a + 5' UTR) along with 1 ng membrane-RFP RNA. 16 Ten-twenty embryos were collected at neurula stages 15-20 11 to make protein lysates as previously described. 19 One embryo equivalent of lysate was run in each well of a 7.5% SDS-PAGE gel. Protein was transferred onto a 0.45 µm PVDF membrane (Thermo Fisher Scientific, Waltham, MA, USA) and blocked overnight in KPL block (SeraCare, Milford, MA, USA) at 4°C. Blots were incubated in rabbit anti-green fluorescent protein (anti-GFP) (1:500, iclLab, Portland, OR, USA) for 24 hours at 4°C or rabbit anti glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH) (1:1000, Santa Cruz, Dallas, TX, USA) for 3 hours at room temperature. Blots were washed with TBS-T, incubated in goat antirabbit IgG horseradish peroxidase secondary antibody (1:3000; Bio-Rad, Hercules, CA, USA) for 1 hour at room temperature, and washed again with TBS-T prior to imaging with Bio-Rad ChemiDoc XRS+(Bio-Rad, Hercules, CA, USA) using SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA).
Imaging
Embryos were scored and photographed using an Olympus SZX16 fluorescent stereomicroscope and Olympus DP71 camera (Olympus, Toyko, Japan). 3G8/4A6 immunostained kidney images were taken using a Zeiss LSM800 confocal microscope (Zeiss, Oberkochen, Germany). Fixed embryos were cleared in a solution of BABB/Murray's clearing solution for confocal imaging (1:2 volume of benzyl alcohol to benzyl benzoate). Images were processed with Adobe Photoshop.
RESULTS
CAKUT/GD identified in patients with DYRK1A mutations
The index patient was seen in Renal Genetics Clinic (RGC) for the evaluation of ID, global DD, Because these variants still lead to other DYRK1A-syndrome features such as ID they may be important for the catalytic activity or conformational stability of DYRK1A. In fact, a patient in a separate DYRK1A structural study had the same R467Q variant, and this residue was found to be a part of a network of electrostatic interactions thought to play a role in the stability of the DYRK1A protein. 22 Out of the three mutations not found in the kinase domain, two are just Nterminal to it (N151fs, K154fs) and the last is found just C-terminal to it in the PEST domain (S494fs). Though, theoretically, all mutations that are more N-terminal should result in NMD, a majority of the mutations reside in the kinase domain for unknown reasons that should be studied further.
Xenopus laevis as a model of GU development
DYRK1A's amino acid sequence is highly conserved among amniotes Figure S1 ). Additionally, the kinase domain, which is where a majority of the mutations that cause CAKUT/GD (in this study) are found, is 97.5% identical (Figure 1) . Importantly, the human and Xenopus kinase activation loop sequences, which is essential for the kinase activity of DYRK1A, are identical.
Xenopus produces large clutch sizes with hundreds of embryos that develop externally, and unilateral embryo injections allow for tissue-targeted knockdowns that are specific to organs such as the kidney. 12 Their embryonic kidney, the pronephros, can easily be visualized and imaged through a transparent epidermis, and they develop a fully functional kidney in ~56 hours. 23 Xenopus was chosen because it is an established model of nephron development, and gene expression studies demonstrate that the developing Xenopus nephron is anatomically and functionally similar to the mammalian nephron. 24, 25 The embryonic pronephros is the precursor to the mesonephric and metanephric kidney in mammals, and subsequent GU development is dependent upon this structure. Specifically, as the pronephros extends toward the cloaca, the mesonephric nephrons form adjacent to the elongating nephric duct, also known as the Wolffian duct. 26 The ureteric bud, which is required for the development of the collecting duct system in mammals, then branches from this duct. Because In vivo knockdown studies in Xenopus assess the role for dyrk1a in renal development.
To examine dyrk1a's role in renal development in Xenopus, anti-sense morpholinos (MO) that block translation were used to knock down endogenous Dyrk1a protein expression. First, the MO was validated by demonstrating through Western blot analysis using a GFP antibody that it correctly targets Xenopus dyrk1a RNA. Two constructs were generated with a GFP tag to demonstrate that the MO targets the endogenous 5' untranslated region (UTR) of dyrk1a's transcript. One construct contains the endogenous transcript's 5' UTR (Figure 2A, bottom) , while the other construct lacks the 5' UTR and serves as a positive control (Figure 2A, top) . 
A mutation identified in DYRK1A-related ID syndrome fails to rescue Dyrk1a loss-offunction in Xenopus.
To assess if patient DYRK1A mutations lead to pronephric anomalies as they do in Xenopus, rescue experiments were carried out upon MO-mediated Dyrk1a knockdown in Xenopus. To express human DYRK1A in Xenopus, constructs with HA tags were generated containing wildtype human DYRK1A RNA and truncated human DYRK1A 205* RNA. Western blot analysis with an HA antibody was used to confirm that these human DYRK1A constructs could be successfully expressed in Xenopus ( Figure 2C ). The anomalies were partially rescued by coinjecting wildtype human DYRK1A RNA ( Figure 3C') . However, the patient-identified truncation DYRK1A 205* RNA failed to rescue these anomalies ( Figure 3D') . Examples of how embryos are scored can be found in Figure S2 . To assess if Dyrk1a affects kidney function a functional assay was performed evaluating edema formation. Edema can be caused by a disruption in the kidneys' ability to excrete excess fluid, but it can also be caused by heart or liver failure. Both the heart and liver arise from dorsal cells in Xenopus (Xenbase.org).
To prevent knockdown in these tissues, embryos were injected with Dyrk1a MO or Standard MO in both ventral cells at the four cell stage to affect both kidneys. Embryos injected with the Dyrk1a MO suffered from edema, characterized by swelling in the chest cavity due to fluid retention ( Figure 3H ) while embryos injected with the Standard MO did not ( Figure 3G ). This technique establishes that loss of dyrk1a affects kidney function in Xenopus. Taken together, these data support a role for DYRK1A in pronephric development and strongly suggest that the DYRK1A R205* mutation is responsible for the kidney anomaly observed in this patient. CAKUT consist of a heterogeneous clinical spectrum, and how CAKUT arise is largely unknown. Thus, it is important to identify all genes and causal variants involved. 31 Strong genetic causality of monogenic disease only accounts for 14% of CAKUT cases, 32 and polygenic causes are speculated to occur but are largely unknown. 33 Next-generation sequencing, specifically ES, has improved the discovery of novel causative genes that are important in GU development. 34, 35, 36 Here, we report on a novel genetic contribution of DYRK1A to CAKUT/GD. We identified 17 unique variants in DYRK1A from clinical ES in 19 unrelated individuals. As summarized in Table 1 , microcephaly, ID, DD, and seizure are some of the more common features of this syndrome.
DISCUSSION
Eleven out of fifteen (73% of those with available data) individuals in this study ( Table 2) have CAKUT/GD, with 33% having renal anomalies, in addition to other organ involvement.
While renal anomalies have been reported previously, 20 broadly based phenotyping for CAKUT was not performed in previous studies.
Seven of the DYRK1A variants identified in our study were novel. Per inclusion criteria, most of DYRK1A variants were de novo and included truncating variants. This suggests a loss-of-function mechanism for variants causing this syndrome which further supports the findings of another group who proposed reduced kinase function as the cause of this syndrome. 22 In addition, we studied the role of dyrk1a in kidney development in Xenopus and found that dyrk1a knockdown results in abnormal tubules or complete loss of the kidney. This phenotype could be partially rescued by human DYRK1A RNA. However, a nonsense mutation failed to rescue the phenotype, indicating that loss-of-function variants in this gene are, in fact, causative for the observed phenotype in some patients. Furthermore, Dyrk1a MO was injected into two cells to affect both kidneys which resulted in edema suggesting that Dyrk1a is important for both kidney development and function. Although Xenopus is an established model to study kidney development, it has not been commonly used to study GD.
However, our findings related to pronephric development are likely relevant to the mammalian GU tract, given the dependence of the formation of the male and female urogenital tract upon the nephric duct and the pronephros.
One limitation of this study is that, we were not able to obtain GU information from all patients in this study. Future plans for research include identification and studying the phenotype and underlying variants in a larger number of affected families. Furthermore, signaling pathways involved in DYRK1A-related CAKUT/GD should be investigated.
In summary, the phenotype of DYRK1A-related ID syndrome is expanded to include CAKUT/GD. Based on our data, we empirically recommend that individuals with DYRK1A syndrome undergo a renal ultrasound and a thorough genital physical exam. Table 2 for more details), ID: Intellectual disability *denotes published patients 
